本頁面由Tiger Trade Technology Pte. Ltd.提供服務

Ultragenyx Pharmaceutical Inc

14.30
+1.4211.02%
成交量:631.66萬
成交額:8,717.03萬
市值:14.06億
市盈率:-2.45
高:14.54
開:13.22
低:13.20
收:12.88
52周最高:39.89
52周最低:12.73
股本:9,831.72萬
流通股本:8,071.56萬
量比:1.50
換手率:7.83%
股息:- -
股息率:- -
每股收益(TTM):-5.8279
每股收益(LYR):-5.8316
淨資產收益率:-608.47%
總資產收益率:-24.22%
市淨率:-4.83
市盈率(LYR):-2.45

資料載入中...

2024/02/13

超過5%披露

Form SC 13G - Statement of acquisition of beneficial ownership by individuals
2024/02/08

超過5%披露

Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
2024/02/08

關聯方擬減持公告

Form 144 - Report of proposed sale of securities
2024/01/08

重要事件披露

Form 8-K - Current report
2023/12/29

關聯方擬減持公告

Form 144 - Report of proposed sale of securities
2023/12/22

重要事件披露

Form 8-K - Current report
2023/11/03

季度報告

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
2023/11/03

重要事件披露

Form 8-K - Current report
2023/10/24

關聯方擬減持公告

Form 144 - Report of proposed sale of securities
2023/10/23

重要事件披露

Form 8-K - Current report
2023/10/20

關聯方擬減持公告

Form 144 - Report of proposed sale of securities
2023/10/19

[補充]招股説明書

Form FWP - Filing under Securities Act Rules 163/433 of free writing prospectuses
2023/10/16

重要事件披露

Form 8-K - Current report
2023/09/12

超過5%披露

Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
2023/09/08

重要事件披露

Form 8-K - Current report
2023/09/07

關聯方擬減持公告

Form 144 - Report of proposed sale of securities
2023/09/05

關聯方擬減持公告

Form 144 - Report of proposed sale of securities
2023/08/04

季度報告

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
2023/08/03

重要事件披露

Form 8-K - Current report
2023/07/12

重要事件披露

Form 8-K - Current report